In this issue of JAMA Psychiatry, Janecka et al1 conclude that maternal prenatal use of most medications that target specific neurotransmitter systems is not associated with offspring autism. This is a new perspective to consider in view of the hypothesis that there could be adverse neurodevelopmental effects of prenatal medications affecting serotonergic, GABAergic, and glutaminergic neurotransmitters. Although results vary,2,3 previous studies have warned of potential bias arising from confounding by maternal indications for prenatal drug treatments, which are stubbornly difficult to resolve.4 Janecka et al1 grouped medications into classes on the basis of each drug’s target neurotransmitter, regardless of the drug’s medical indication, and then estimated autism risk associated with maternal use of a drug in a class targeting a common neurotransmitter. They called this a biology-first approach to highlight that their autism risk assessment was linked to the drugs’ shared pharmacological effect and functional similarities while disassociated from the underlying indication.
Schendel D, Christensen J, Rai D. A Biology-First Approach in Perinatal Pharmacoepidemiology of AutismPotential and Pitfalls. JAMA Psychiatry. 2018;75(12):1213–1214. doi:10.1001/jamapsychiatry.2018.2725
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: